Infertility Clinical Trial
Official title:
Humidified Incubator Effect on Live Birth Rate After ICSI
Verified date | June 2020 |
Source | Ibn Sina Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Humidity for human embryo culture has been raised as essential with advantageous effect on clinical pregnancy and ongoing pregnancy after ICSI compared with a dry incubator. Whether the deleterious effect of dry culture would have an extended effect reaches the live birth rate needs to be examined. This RCT is to examine the effect of dry and humidified culture on live birth rates after ICSI.
Status | Completed |
Enrollment | 1837 |
Est. completion date | March 27, 2020 |
Est. primary completion date | March 27, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: - Women undergoing a first or second ICSI attempts - Primary or secondary infertility with a BMI of < 31 kg/m2 - Duration of infertility of = 18 months and normal baseline ultrasonography - 18 to 40 years of age - Tubal factor, male factor, polycystic ovary, unexplained infertility or combined factors - Tubal factors Exclusion Criteria: - Surgically-retrieved, frozen-thawed and pinpoint sperm or globozoospermia - Thin endometrium - Uterine anomaly and adhesion - Adenomyosis - Submucous myoma - Endometriosis - Severe medical condition |
Country | Name | City | State |
---|---|---|---|
Egypt | Banon Assiut | Assiut | |
Egypt | Qena Fertility Center | Qena | |
Egypt | IbnSina IVF Center | Sohag |
Lead Sponsor | Collaborator |
---|---|
Ibn Sina Hospital | Amshag IVF Center, Banoon IVF Center, Quena IVF Center |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Live birth rate | Viable neonate after 30 weeks of gestation per initiated cycle | 30 weeks | |
Secondary | Cumulative live birth rate | Viable neonate after 30 weeks of gestation after one fresh and/or one frozen-warmed transfer per initiated cycle | One year | |
Secondary | Ongoing pregnancy rate | Continued pregnancy after 12 weeks of gestation per initiated cycle | 12 weeks of gestation | |
Secondary | Cumulative ongoing pregnancy rate | Continued pregnancy after 12 weeks of gestation per initiated cycle within one year of randomization | 12 weeks of gestation | |
Secondary | Clinical pregnancy rate | Ultrasound detect heartbeat after 7 weeks of gestation per initiated cycle | 7 weeks of gestation | |
Secondary | Cumulative clinical pregnancy rate | Ultrasound detect heartbeat after 7 weeks of gestation per initiated cycle within one year of randomization | 7 weeks of gestation | |
Secondary | Implantation rate | Number of sacs with a heartbeat per number of embryo transferred | 7 weeks of gestation | |
Secondary | Cumulative implantation rate | Number of sacs with a heartbeat per number of embryo transferred within one year of randomization | 7 weeks of gestation | |
Secondary | Ongoing implantation rate | Number of sacs with a heartbeat per number of embryo transferred | 12 weeks of gestation | |
Secondary | Cumulative ongoing implantation rate | Number of sacs with a heartbeat per number of embryo transferred within one year of randomization | 12 weeks of gestation | |
Secondary | Preterm birth rate | number of babies born before 37 weeks of gestation per total birth | 37 weeks | |
Secondary | Very preterm birth | number of babies born before 32 weeks of gestation per total birth | 32 weeks | |
Secondary | Low birth weight rate | number of babies with < 2500 gm per total birth | 40 weeks of gestation | |
Secondary | Fertilization rate | fertilized oocytes with two pronuclei per Metaphase II injected | 6 days of culture | |
Secondary | Cleavage rate | Cleaved embryo per fertilized oocyte | 6 days of culture | |
Secondary | Rate of high-quality day-3 embryos | Embryos with seven or eight blastomeres of appropriate-size, and < 10% fragmentation by volume per fertilized oocyte | 6 days of culture | |
Secondary | Blastocyst formation rate | Formed blastocyst on day 5/6 from fertilized oocytes | 6 days of culture | |
Secondary | Rate of high-quality blastocyst | Blastocysts = 3.1.1 grade per fertilized oocyte | 6 days of culture | |
Secondary | Rate of utilizable blastocyst | Transferred and cryopreserved blastocysts from fertilized oocytes | 6 days of culture |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A |